4/A: Palisade Bio Amends Director RSU Grant, Reduces by 88%

Palisade Bio, Inc. filed an amended Form 4, significantly reducing Director Donald Allen Williams' Restricted Stock Unit grant from 1,538,700 to 182,000 units.

Summary

• Palisade Bio, Inc. (PALI) filed an amended Form 4 to correct a previously reported Restricted Stock Unit (RSU) grant for Director Donald Allen Williams.
• The original grant of 1,538,700 RSUs has been rescinded by 1,356,700 RSUs.
• The corrected RSU grant amount for Donald Allen Williams is now 182,000 units.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, or cash if sufficient shares are not reserved under the 2021 Equity Incentive Plan.
• The RSUs are subject to service-based vesting in three equal annual installments.
• The first installment vests on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, contingent on continuous service.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the correction of an error, indicating good governance and transparency, despite the initial reporting mistake. The reduction in potential dilution is also a minor positive.

Positives

• The company demonstrated transparency and good corporate governance by correcting an error in a previously reported RSU grant.
• The reduction in the RSU grant for the director means less potential future dilution from this specific grant than initially reported.

Negatives

• The initial error in reporting a significant RSU grant amount could suggest a lapse in internal controls or reporting accuracy.
• Director Donald Allen Williams will receive significantly less equity compensation (182,000 RSUs) than the initially reported 1,538,700 RSUs.

Future Outlook

The granted Restricted Stock Units are subject to a service-based vesting schedule, with the first of three equal annual installments vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025, provided the reporting person maintains continuous service.

Industry Context

This filing is a standard disclosure related to executive compensation and corporate governance, common across publicly traded companies. It reflects the ongoing process of managing equity incentive plans and ensuring accurate reporting of director compensation.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from this specific RSU grant is reduced compared to the initially reported amount.
• Director Donald Allen Williams: Receives significantly less equity compensation than initially reported, impacting personal compensation.

Next Steps

• The RSUs will vest in three equal annual installments, with the first installment vesting on the earlier of the 2026 annual meeting of stockholders or the anniversary of October 6, 2025.

Key Dates

Keywords

Palisade Bio, PALI, Restricted Stock Units, RSU, Form 4/A, SEC filing, Director compensation, Equity incentive plan, Corporate governance